Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) EBIT Margin: 2020-2024

Historic EBIT Margin for Fulcrum Therapeutics (FULC) over the last 4 years, with Jun 2024 value amounting to 65.61%.

  • Fulcrum Therapeutics' EBIT Margin rose 316698.00% to 65.61% in Q2 2024 from the same period last year, while for Jun 2024 it was -39.72%, marking a year-over-year increase of 349495.00%. This contributed to the annual value of -27.37% for FY2024, which is 391787.00% up from last year.
  • According to the latest figures from Q2 2024, Fulcrum Therapeutics' EBIT Margin is 65.61%, which was up 102.04% from -3,213.78% recorded in Q4 2023.
  • Over the past 5 years, Fulcrum Therapeutics' EBIT Margin peaked at 65.61% during Q2 2024, and registered a low of -9,471.19% during Q1 2023.
  • Moreover, its 3-year median value for EBIT Margin was -3,101.36% (2023), whereas its average is -3,144.50%.
  • In the last 5 years, Fulcrum Therapeutics' EBIT Margin crashed by 846,818bps in 2023 and then surged by 316,698bps in 2024.
  • Fulcrum Therapeutics' EBIT Margin (Quarterly) stood at -420.99% in 2020, then slumped by 4,478bps to -465.78% in 2021, then crashed by 361,787bps to -4,083.65% in 2022, then surged by 86,987bps to -3,213.78% in 2023, then soared by 316,698bps to 65.61% in 2024.
  • Its last three reported values are 65.61% in Q2 2024, -3,213.78% for Q4 2023, and -3,615.28% during Q3 2023.